GLP-1 Agonist Approved (outside US)

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

The most widely prescribed GLP-1 agonist for weight loss and type 2 diabetes, delivering ~15% body weight reduction with once-weekly dosing.

Popularity A+
Class GLP-1 Receptor Agonist
Half-Life ~7 days (168 hours)
Form Pre-filled pen, Lyophilized powder, Oral tablet
View Vendors → Jump to Dosing ↓
Semaglutide C187H291N45O59
Research-Backed User Reports Sourced Updated Mar 2026
// Overview

What is Semaglutide?

Semaglutide (brand names Ozempic, Wegovy, Rybelsus) is a glucagon-like peptide-1 (GLP-1) receptor agonist that has become the most widely prescribed weight loss medication in history. Originally developed by Novo Nordisk for type 2 diabetes, its profound effects on appetite and body weight led to its approval for obesity management.

The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly injection produced an average of 14.9% body weight loss over 68 weeks. This made it the most effective anti-obesity medication available until tirzepatide emerged with even greater efficacy.

Semaglutide mimics the natural incretin hormone GLP-1, binding to GLP-1 receptors in the pancreas, gut, and brain. Its albumin-binding side chain gives it a long half-life of approximately one week, allowing once-weekly dosing.

Looking for the best vendor deals?

Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.

Compare Vendors
// How It Works

How Semaglutide Works

Semaglutide is a modified GLP-1 analog with 94% homology to native GLP-1. Its mechanism involves:

  1. Appetite suppression — Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and increase satiety. Users describe this as a dramatic reduction in "food noise."
  2. Gastric slowing — Delays gastric emptying by 30-40%, prolonging the feeling of fullness after meals and reducing meal size.
  3. Insulin regulation — Enhances glucose-dependent insulin secretion and suppresses glucagon, improving glycemic control without hypoglycemia risk.
  4. Albumin binding — A C-18 fatty acid sidechain binds to serum albumin, extending the half-life to ~7 days for once-weekly dosing.
// Dosage Protocols

Dosage Information (User-Reported)

Disclaimer: Dosage information is compiled from user reports and published research. This is not medical advice. Consult a healthcare professional before use.
Level Dose Frequency Duration
Starter 0.25 mg Once weekly 4 weeks
Titration 0.5 mg Once weekly 4 weeks
Therapeutic Low 1.0 mg Once weekly 4+ weeks
Therapeutic Mid 1.7 mg Once weekly 4+ weeks
Therapeutic High 2.4 mg Once weekly Ongoing

What to Expect

Week 1-4

Mild appetite changes at 0.25mg. Some nausea. Most users notice reduced snacking urges within first 2 weeks.

Week 5-8

Noticeable appetite suppression at 0.5mg. Food noise significantly reduced. Average 3-5% body weight loss.

Month 3-6

Strong satiety effects at 1.0-1.7mg. Consistent 1-2 lb/week loss. GI side effects typically resolve.

Month 6-12+

Peak weight loss at 2.4mg. Users report 12-17% total body weight reduction. Metabolic markers improve significantly.

Common Stacks

BPC-157

GI Protection

Mitigates nausea and gastric discomfort from GLP-1 receptor activation

Creatine Monohydrate

Muscle Preservation

Helps maintain lean mass during caloric deficit and rapid weight loss

L-Carnitine

Enhanced Fat Oxidation

Supports mitochondrial fatty acid transport during accelerated lipolysis

// Preparation

Reconstitution & Storage

If using lyophilized research-grade powder: Reconstitute with bacteriostatic water. Add water gently — do not shake. Swirl until dissolved. Refrigerate and use within 28 days.

Storage: Refrigerate 2-8°C before first use. In-use pen: room temp up to 30°C for 56 days.

Ready to source Semaglutide?

Compare prices across verified vendors. Find the best purity at the lowest price.

Compare Vendors →
// Safety Profile

Side Effects & Safety

Potential Side Effects

  • ! Nausea (44% incidence, usually resolves with titration)
  • ! Diarrhea
  • ! Vomiting
  • ! Constipation
  • ! Abdominal pain
  • ! Injection site reactions
  • ! Fatigue and dizziness
  • ! Gallbladder issues with rapid weight loss
  • ! Pancreatitis (rare)

Contraindications

  • ⚠ Personal or family history of medullary thyroid carcinoma (MTC)
  • ⚠ Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • ⚠ History of pancreatitis
  • ⚠ Pregnancy or breastfeeding
  • ⚠ Severe renal impairment

Legal & Regulatory Status

FDA-approved as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral, T2D). Prescription-only. Compounded versions have been available through 503A/503B pharmacies. Research-grade semaglutide available from peptide suppliers for research purposes.

// Research

Published Research

// Where to Buy

Top Vendors for Semaglutide

Ranked by our review scores. All vendors are independently tested.

B+
Read Review Visit Vendor →
B+
Read Review Visit Vendor →
B+
Read Review Visit Vendor →
// Related Compounds

Other GLP-1 Agonist Guides

Cagrilintide

A long-acting amylin analog that amplifies weight loss when paired with semaglutide — the amylin component of CagriSema's…

Read Guide →

BPC-157 Arginate (Oral)

The oral form of BPC-157 — gastric-acid stable and designed for direct GI tract healing. No injections needed…

Read Guide →

TB-500 Fragment

A concentrated fragment of Thymosin Beta-4 focused on the core actin-binding domain — smaller molecule, targeted tissue repair.

Read Guide →

Stay informed on Semaglutide.

New research, dosage updates, and vendor deals. Straight to your inbox.

Free forever. No spam. Unsubscribe anytime.

This content is for informational and educational purposes only. Semaglutide is sold for research purposes. Never Natty does not condone or encourage the use of any substance in violation of any laws. Consult a healthcare professional before using any compound discussed on this site.